Advertisement
Advertisement
RGEN
Repligen Corp
176.12
USDSponsored
-12.52
-6.63%
Oct 30, 15:45 UTC -4
Open
Repligen Corp (RGEN) Earnings
RGEN Earnings Reports
Positive Surprise Ratio
RGEN beat 37 of 44 last estimates.
84%
Next Report
Date of Next Report
Feb 22, 2027
Estimate for Q4 26 (Revenue/ EPS)
$229.66M
/$0.58
Implied change from Q3 26 (Revenue/ EPS)
+9.72%
/+9.43%
Implied change from Q4 25 (Revenue/ EPS)
+16.04%
/+18.37%
Repligen Corp earnings per share and revenue
On Oct 27, 2026, RGEN reported earnings of 0.53 USD per share (EPS) for Q3 26, beating the estimate of 0.46 USD, resulting in a 12.79% surprise. Revenue reached 209.31 million, compared to an expected 210.75 million, with a -0.68% difference. The market reacted with a -2.43% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.58 USD, with revenue projected to reach 229.66 million USD, implying an increase of 9.43% EPS, and increase of 9.72% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Insmed, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.46
Surprise
-19.82%
Incyte Genomics Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$3.92
Actual
-$3.60
Surprise
+8.33%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
PTC Therapeutics, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.34
Actual
$0.61
Surprise
+75.59%
Fortrea Holdings Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.22
Actual
$0.28
Surprise
+26.53%
FAQ
What were Repligen Corp's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Repligen Corp reported EPS of $0.53, beating estimates by 12.79%, and revenue of $209.31M, -0.68% below expectations.
How did the market react to Repligen Corp's Q3 2026 earnings?
The stock price moved down -2.43%, changed from $180.17 before the earnings release to $175.80 the day after.
When is Repligen Corp expected to report next?
The next earning report is scheduled for Feb 22, 2027.
What are the forecasts for Repligen Corp's next earnings report?
Based on --
analysts, Repligen Corp is expected to report EPS of $0.58 and revenue of $229.66M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.